EBElena O. Belyaeva

Elena O. Belyaeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena O. Belyaeva has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A novel approach for simultaneous detection of structural and single-nucleotide variants based on a combination of chromosome conformation capture and exome sequencing

    by Maria Gridina, Timofey Lagunov, Polina Belokopytova, Nikita Torgunakov, Miroslav Nuriddinov, Artem Nurislamov, Lyudmila P Nazarenko, Anna A Kashevarova, Maria E Lopatkina, Elena O Belyaeva, et al.

    Effective molecular diagnosis of congenital diseases hinges on comprehensive genomic analysis, traditionally reliant on various methodologies specific to each variant type—whole exome or genome sequencing for single nucleotide variants (SNVs), array CGH for copy-number variants (CNVs), and microscopy for structural variants (SVs). We introduce a novel, integrative approach combining exome sequencing with chromosome conformation capture, termed Exo-C. This method enables the concurrent identification of SNVs in clinically relevant genes and SVs across the genome and allows analysis of heterozygous and mosaic carriers. Enhanced with targeted long-read sequencing, Exo-C evolves into a cost-efficient solution capable of resolving complex SVs at base-pair accuracy. Through several case studies, we demonstrate how Exo-C’s multifaceted application can effectively uncover diverse causative variants and elucidate disease mechanisms in patients with rare disorders.

  • Open Access

    Experience in genetic testing of hypertrophic cardiomyopathy using nanopore DNA sequencing

    by R. R. Salakhov, M. V. Golubenko, E. N. Pavlukova, A. N. Kucher, N. P. Babushkina, N. R. Valiahmetov, A. V. Markov, E. O. Belyaeva, A. F. Kanev, M. S. Nazarenko

    Aim. To investigate the application of the Oxford Nanopore Technologies’ third generation sequencing for the genetic testing of hypertrophic cardiomyopathy.Material and methods. The study involved 12 patients with hypertrophic cardiomyopathy aged 18 to 67 years (women, 9; men, 3). Using the PCR barcoding amplicons (SQK-LSK109) protocol, DNA libraries were created which contained long-range PCR fragments of the MYH7, MYBPC3, TNNT2, TNNI3 and TPM1 genes. The sequencing was performed using the MinION system by Oxford Nanopore Technologies (UK). Bioinformatic algorithms for data analysis included Guppy v.5.0.7, Nanopolish and Clairvoyante. The identified genetic variants were confirmed by Sanger sequencing.Results. Data on the complete sequence of the five major sarcomeric genes for hypertrophic cardiomyopathy were obtained. We found eight potentially disease-causing sequence variants in MYH7, MYBPC3 and TNNT2 genes by monomolecular sequencing. However, only three mutations p.Arg243Cys, p.Tyr609Asn, p.Arg870His in the MYH7 gene, and one mutation p.Lys985Asn in the MYBPC3 were confirmed by Sanger sequencing. Cascade screening of pathogenic variant p.Arg870His in the MYH7 gene was performed. We found one asymptomatic carrier.Conclusion. It appears that monomolecular sequencing technology is a feasible approach to identify mutations in patients with hypertrophic cardiomyopathy. Although improvement in accuracy of DNA sequencing, as well as optimization and simplification of bioinformatic algorithms for identification of the genetic variants are needed.


  • Анализ спектра мутаций в генах COL1A1 и COL1A2 с использованием массового параллельного секвенирования у больных несовершенным остеогенезом в Томской области

    by N.A. Skryabin, O.Yu. Vasilyeva, A.A. Sivtsev, I.Zh. Zhalsanova, А. Е. Постригань, L.I. Minaicheva, А. А. Агафонова, В. В. Петрова, Л. П. Назаренко, Г. Н. Сеитова, et al.

    Проведен поиск мутаций в генах COL1A1 и COL1A2 с использованием массового параллельного секвенирования у 16 больных из 10 семей с несовершенным остеогенезом I, III и IV типов. Для анализа мутаций в данных генах была разработана панель праймеров для секвенирования полной последовательности генов. В результате проведенной работы выявлено 10 мутаций: шесть из них расположены в гене COL1A1, четыре мутации – в гене COL1A2. Все мутации, кроме одной, были ранее описаны в литературе и встречались у пациентов с различными типами несовершенного остеогенеза. В пяти семьях были выявлены миссенс-мутации, в двух семьях – нонсенс мутации, еще в двух случаях – мутации в сайтах сплайсинга и у одного пациента – мутация со сдвигом рамки считывания. Во всех семьях были найдены уникальные мутации, не повторяющиеся у неродственных пациентов. Выявленная высокая гетерогенность спектра мутаций в генах COL1A1 и COL1A2 при несовершенном остеогенезе указывает на эффективность использования методов, основанных на технологии массового параллельного секвенирования для диагностики данной патологии.


  • Open Access

    Compound phenotype in a girl with r(22), concomitant microdeletion 22q13.32-q13.33 and mosaic monosomy 22

    by Anna A. Kashevarova, Elena O. Belyaeva, Aleksandr M. Nikonov, Olga V. Plotnikova, Nikolay A. Skryabin, Tatyana V. Nikitina, Stanislav A. Vasilyev, Yulia S. Yakovleva, Nadezda P. Babushkina, Ekaterina N. Tolmacheva, et al.

    Ring chromosome instability may influence a patient’s phenotype and challenge its interpretation. Here, we report a 4-year-old girl with a compound phenotype. Cytogenetic analysis revealed her karyotype to be 46,XX,r(22). aCGH identified a 180 kb 22q13.32 duplication, a de novo 2.024 Mb subtelomeric 22q13.32-q13.33 deletion, which is associated with Phelan-McDermid syndrome, and a maternal single gene 382-kb TUSC7 deletion of uncertain clinical significance located in the region of the 3q13.31 deletion syndrome. All chromosomal aberrations were confirmed by real-time PCR in lymphocytes and detected in skin fibroblasts. The deletions were also found in the buccal epithelium. According to FISH analysis, 8% and 24% of the patient’s lymphocytes and skin fibroblasts, respectively, had monosomy 22. We believe that a combination of 22q13.32-q13.33 deletion and monosomy 22 in a portion of cells can better define the clinical phenotype of the patient. Importantly, the in vivo presence of monosomic cells indicates ring chromosome instability, which may favor karyotype correction that is significant for the development of chromosomal therapy protocols.